Alantolactone selectively ablates acute myeloid leukemia stem and progenitor cells

BACKGROUND: The poor outcomes for patients diagnosed with acute myeloid leukemia (AML) are largely attributed to leukemia stem cells (LSCs) which are difficult to eliminate with conventional therapy and responsible for relapse. Thus, new therapeutic strategies which could selectively target LSCs in...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Yahui, Gao, Huier, Zhang, Yu, Li, Ye, Vasdev, Neil, Gao, Yingdai, Chen, Yue, Zhang, Quan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5034521/
https://www.ncbi.nlm.nih.gov/pubmed/27658462
http://dx.doi.org/10.1186/s13045-016-0327-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5034521/
https://www.ncbi.nlm.nih.gov/pubmed/27658462
http://dx.doi.org/10.1186/s13045-016-0327-5

Ejemplares similares